JAK-STAT and IL-23/Th17 Pathway in Psoriasis and IBD: Environmental Triggers and Therapeutic Targets

Central Question

How do environmental factors interact with the JAK-STAT and IL-23/Th17 pathway in psoriasis and inflammatory bowel disease?

Background

The JAK-STAT pathway transduces signals from cytokines including IL-23, which drives Th17 differentiation and is central to psoriasis and inflammatory bowel disease (Crohn disease, ulcerative colitis). HLA-C*06:02 and IL23R are major genetic risk factors. Environmental triggers—stress, infection, diet, smoking (with opposite effects in Crohn vs UC), and medications—can precipitate or exacerbate disease. JAK inhibitors and anti–IL-23 biologics are effective therapies. This brief summarizes the mechanistic link between JAK-STAT/IL-23 genetics, environmental modifiers, and autoimmune disease expression.

Evidence Summary

  • GWAS: IL23R and JAK-STAT pathway genes are shared between psoriasis and IBD; HLA and other loci are disease-specific.
  • Environmental: Stress and infection can trigger psoriasis flares; smoking increases Crohn risk but may decrease UC risk; diet and microbiome modulate IBD.
  • Therapeutic: JAK inhibitors and anti–IL-23/IL-12 agents are approved for psoriasis and IBD; support central role of pathway.

Mechanistic Chain

  1. 1. IL-23 from dendritic cells and macrophages binds IL-23R on T cells and ILCs.
  2. 2. JAK-STAT signaling drives Th17 differentiation and production of IL-17, IL-22.
  3. 3. In psoriasis: Th17 cytokines promote keratinocyte proliferation and skin inflammation; stress and infection can amplify cytokine release.
  4. 4. In IBD: Th17 response to gut microbiota and barrier breach; diet and smoking alter microbiome and barrier.
  5. 5. Genetic risk (IL23R, HLA) sets susceptibility; environmental triggers determine timing and severity of flares.

Tissue Specificity

Psoriasis: skin (epidermis, dermis). IBD: intestinal epithelium and lamina propria. JAK-STAT and IL-23/Th17 are active in lymphoid and barrier tissues.

Counterarguments / Limitations

  • Precise G×E (e.g., IL23R × specific trigger) is not well characterized; most evidence is genetic main effects and environmental main effects.
  • Smoking paradox in CD vs UC suggests complex, disease-specific environmental effects.

Validation Criteria

  • Prospective cohort with genotype and environmental exposure assessment; test for G×E on psoriasis/IBD incidence and flare.
  • Mechanistic studies of IL-23/Th17 response under stress or dietary intervention in risk genotype carriers.

References

  1. 1.O'Shea JJ, et al. (2015). JAK-STAT signaling in immune regulation. Immunity. doi:10.1016/j.immuni.2015.02.010
  2. 2.Schwartz DM, et al. (2017). Targeting the JAK/STAT pathway in autoimmune disease. Nature Reviews Drug Discovery. doi:10.1038/nrd.2017.201